Japan Tobacco Inc.
http://www.jt.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Japan Tobacco Inc.
Leo’s New Growth Driver Anzupgo Poised For EU Approval
The JAK inhibitor cream for hand eczema will serve a large market in Europe and help the Danish dermatology specialist expand its strong position in dermatology.
Orphan Drug, Domestic Developers Shine In China Annual Approvals Tally
10 orphan drugs imported from overseas, and 40 new drug approvals, including many from domestic developers, capped 2023 as one of the busiest years for China's drug regulatory agency, as Beijing pivoted to emphasizing affordable innovation and expanding access to newer therapies for rare conditions.
Leo Looks For More Deals After Sealing Timber Buy
The Danish group’s pursuit of Timber, and its late-stage congenital ichthyosis therapy, has finally reached a successful conclusion and CEO Christophe Bourdon tells Scrip that the search is on for more innovative assets.
Podcast: China CEO Interview – Gracell Aims To Enter US CAR-T Sector Through Partnerships, Faster Delivery
With the success of the partnership between J&J and partner Legend, more Chinese cell therapy developers are now looking to enter the US market. But for a complex product like a CAR-T therapy, the journey to the West is not short of challenges. Nasdaq-listed Gracell Bio wants to give it a shot based on quicker delivery and cost-effectiveness advantages.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Akros Pharma
- Donskoy Tabak
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice